Ultrasound study for PRRT response in GEP-NET
Part of Cancer clinical trials.
This trial tests if a special ultrasound can help doctors see how well treatment is working for a type of slow-growing gut or pancreas cancer (GEP-NET). It may help guide your care if you are starting a therapy called PRRT (peptide receptor radionuclide therapy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a well-differentiated GEP-NET (a type of neuroendocrine tumor in the gut or pancreas) that cannot be removed by surgery and has a growth score (Ki67) between 2% and 55%.
- Your tumor cells show high levels of somatostatin receptors (a protein that acts like a target for the treatment) on a PET or SPECT scan.
- You have at least one tumor that can be measured by a standard CT or MRI scan.
- You sign a consent form and agree to follow the study procedures.
- You are not allergic to the radioactive medicine Lutetium-177 used in PRRT.
- You have no other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Hear when a new Contrast Enhanced Ultrasound trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.